Tweets
Polymyalgia rheumatica: more than just steroids at #ACR22
After decades of having little else proven apart from glucocorticosteroids with which to treat PMR, evidence for steroid-sparing options has grown in recent years.
https://t.co/CjMzEqRan8 https://t.co/5UixhVemqY
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
SMS/email reminders slightly improve fluvax uptake in RA pts
(nested RCT within ART registry, France)
ABST2002 #ACR22 @RheumNow
@philipcrobinson & I wrote @TheLancetRheum on how to improve preventative med https://t.co/55j8rdv3nV
I think we need multiple simultaneous strategies! https://t.co/pNfpWLVkac
David Liew @drdavidliew ( View Tweet )
3 years 8 months ago
Big change for #SLE Trials coming soon.
My exclusive interview w/Prof @EricFMorand. Future trials will likely incorporate this Novel Treatment Response Measurement (TRM) Tool #ACR22 @rheumnow https://t.co/TXsxJi3qhC
TheDaoIndex @KDAO2011 ( View Tweet )
3 years 8 months ago
Our work presented at #ACR22 showing increased mast cells and tryptase activity in women with OA compared to men!
Food for thought - can simple allergy meds help in OA management?
@RheumNow abst#1642. https://t.co/cBQZU5MXeR
Bella Mehta @bella_mehta ( View Tweet )
3 years 8 months ago
Cancer risk with tofacitinib vs TNFi in RA:
we learned at #ACR21 that
CV-enriched pts: risk (ORAL Surveillance)
all comers: no risk (STAR-RA)
French national healthcare database #ACR22 looks at all comers: nothing to separate tofa and TNFi.
Risk begets risk
ABST1984 @RheumNow https://t.co/0GG04NSP3D https://t.co/nwQz7fx21M
David Liew @drdavidliew ( View Tweet )
3 years 8 months ago
Based on your experience, will you attend #ACR23 next year ... @ACRheum @rheumnow
TheDaoIndex @KDAO2011 ( View Tweet )
3 years 8 months ago
⚡️Pulmonary pulse wave transit time⚡️
👉novel non-invasive echo measure of ⬆️pulm vasc tone in pulm HTN
👉hyperuricaemic pts ⬇️pPTT sugg of pulm vasc dysfn
@FloodRachael #ACR22 Abst1788 @RheumNow https://t.co/ZEORWbqw6f
Patricia Harkins @DrTrishHarkins ( View Tweet )
3 years 8 months ago
Still for me the most interesting bit from the GLORIA study (PNL 5 add-on in RA) is the coming off of it.
Patients were able to come off their long-term low-dose prednisolone. No Sx/biochem differences vs placebo.
True #squadgoals for rheumatologists
ABST2000 #ACR22 @RheumNow https://t.co/eQLcgqA1SN https://t.co/RGTCrMhld7
David Liew @drdavidliew ( View Tweet )
3 years 8 months ago
Cumulative dose and exposure to methotrexate were not predictors of hepatic fibrosis.
Hepatic fibrosis as measured by elastography associated with daily EtOH use.
#ACRBest Abs#2147 @RheumNow #ACR22
Robert B Chao, MD @doctorRBC ( View Tweet )
3 years 8 months ago
Peritonitis of the #FMF - misdiagnosed as acute abdomen
Acute appendicitis is the leading cause of acute abdomen in FMF
Turkish study 1655 #FMF pts
15.8% appendectomy rates!
CRP ineffective for differing FMF from appendicitis :(
@RheumNow #ACR22 abst#1839
Bella Mehta @bella_mehta ( View Tweet )
3 years 8 months ago
Factors associated with non-achievement of MDA in PsA pts receiving golimumab:
Baseline tender joint count, fibromyalgia, older age, smoking, high BMI
Abs#2109 @RheumNow #ACR22 https://t.co/dEzQxVtavh
Robert B Chao, MD @doctorRBC ( View Tweet )
3 years 8 months ago
‼️‼️Frailty ‼️‼️
👉Important predictor of serious infxn in RA pts on b- or tsDMARD irrespective of age ‼️‼️
@NamrataRheum illustrating yet another reason why it is so NB to evaluate 4 frailty in ALL (incl young) pts with RA
#GeriRheum
Abst2218 @RheumNow #ACR22 https://t.co/J4XQFmVoUw
Patricia Harkins @DrTrishHarkins ( View Tweet )
3 years 8 months ago
